ADC Therapeutics S.A. (ADCT) Stock Analysis & Winston Score

ADC Therapeutics is a Swiss biotech company that develops cancer-fighting drugs called antibody-drug conjugates, or ADCs. These are medicines that work like guided missiles — they attach to cancer cells and deliver a toxic payload directly to them, leaving healthy cells mostly alone. The company's main approved product is Zynlonta, a treatment for certain types of blood cancer called B-cell lymphoma, sold primarily to oncologists and hospitals in the United States. The company makes money by selling Zynlonta to healthcare providers, and it also earns fees by licensing its ADC technology to other pharmaceutical companies. ADC Therapeutics operates mainly in the U.S. and Europe, and with a market cap around $400 million, it is a small player in a competitive field. The deep operating losses reflect heavy spending on research and clinical trials, and the key risk is whether the company can expand Zynlonta's approved uses fast enough to reach profitability before needing to raise more cash.